Literature DB >> 19426677

Electrophysiologic characterization of a novel hERG channel activator.

Zhi Su1, James Limberis, Andrew Souers, Philip Kym, Ann Mikhail, Kathryn Houseman, Gilbert Diaz, Xiaoqin Liu, Ruth L Martin, Bryan F Cox, Gary A Gintant.   

Abstract

Activators of the human ether-a-go-go-related gene (hERG) K(+) channel have been reported recently to enhance hERG current amplitude (five synthetic small molecules and one naturally occurring substance). Here, we characterize the effects of a novel compound A-935142 ({4-[4-(5-trifluoromethyl-1H-pyrazol-3-yl)-phenyl]-cyclohexyl}-acetic acid) on guinea-pig atrial and canine ventricular action potentials (microelectrode techniques) and hERG channels expressed in HEK-293 cells (whole-cell patch clamp techniques). A-935142 shortened cardiac action potentials and enhanced the amplitude of the hERG current in a concentration- and voltage-dependent manner. The fully activated current-voltage relationship revealed that this compound (60 microM) increased both outward and inward K(+) current as well as the slope conductance of the linear portion of the fully activated I-V relation. A-935142 significantly reduced the time constants (tau) of hERG channel activation at two example voltages (-10 mV: tau=100+/-17 ms vs. 164+/-24 ms, n=6, P<0.01; +30 mV: tau=16.7+/-1.8 ms vs. 18.9+/-1.8 ms, n=5, P<0.05) and shifted the voltage-dependence for hERG activation in the hyperpolarizing direction by 9 mV. The time course of hERG channel deactivation was slowed at multiple potentials (-120 to -70 mV). A-935142 also reduced the rate of inactivation and shifted the voltage-dependence of inactivation in the depolarizing direction by 15 mV. Recovery of hERG channel from inactivation was not affected by A-935142. In conclusion, A-935142 enhances hERG current in a complex manner by facilitation of activation, reduction of inactivation, and slowing of deactivation, and abbreviates atrial and ventricular repolarization.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19426677     DOI: 10.1016/j.bcp.2009.01.015

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  16 in total

Review 1.  Revealing the structural basis of action of hERG potassium channel activators and blockers.

Authors:  Matthew Perry; Michael Sanguinetti; John Mitcheson
Journal:  J Physiol       Date:  2010-07-19       Impact factor: 5.182

2.  Molecular determinants of human ether-à-go-go-related gene 1 (hERG1) K+ channel activation by NS1643.

Authors:  Morten Grunnet; Jennifer Abbruzzese; Frank B Sachse; Michael C Sanguinetti
Journal:  Mol Pharmacol       Date:  2010-09-27       Impact factor: 4.436

3.  Activation of HERG channels: opening new applications for the biophysics of antiarrhythmic therapy.

Authors:  Randall L Rasmusson; Justus M Anumonwo
Journal:  Biophys J       Date:  2015-03-24       Impact factor: 4.033

4.  Modulation of Kv 11.1 (hERG) channels by 5-(((1H-indazol-5-yl)oxy)methyl)-N-(4-(trifluoromethoxy)phenyl)pyrimidin-2-amine (ITP-2), a novel small molecule activator.

Authors:  Harinath Sale; Samrat Roy; Jayakumar Warrier; Srinivasan Thangathirupathy; Yoganand Vadari; Shruthi K Gopal; Prasad Krishnamurthy; Manjunath Ramarao
Journal:  Br J Pharmacol       Date:  2017-06-18       Impact factor: 8.739

5.  Modulation of hERG potassium channel gating normalizes action potential duration prolonged by dysfunctional KCNQ1 potassium channel.

Authors:  Hongkang Zhang; Beiyan Zou; Haibo Yu; Alessandra Moretti; Xiaoying Wang; Wei Yan; Joseph J Babcock; Milena Bellin; Owen B McManus; Gordon Tomaselli; Fajun Nan; Karl-Ludwig Laugwitz; Min Li
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-28       Impact factor: 11.205

6.  Pharmacological and electrophysiological characterization of AZSMO-23, an activator of the hERG K(+) channel.

Authors:  R Mannikko; M H Bridgland-Taylor; H Pye; S Swallow; N Abi-Gerges; M J Morton; C E Pollard
Journal:  Br J Pharmacol       Date:  2015-04-10       Impact factor: 8.739

Review 7.  Activation of human ether-a-go-go related gene (hERG) potassium channels by small molecules.

Authors:  Ping-zheng Zhou; Joseph Babcock; Lian-qing Liu; Min Li; Zhao-bing Gao
Journal:  Acta Pharmacol Sin       Date:  2011-05-30       Impact factor: 6.150

Review 8.  Voltage-gated potassium channels as therapeutic targets.

Authors:  Heike Wulff; Neil A Castle; Luis A Pardo
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

Review 9.  HERG1 channel agonists and cardiac arrhythmia.

Authors:  Michael C Sanguinetti
Journal:  Curr Opin Pharmacol       Date:  2013-11-27       Impact factor: 5.547

10.  In vivo arrhythmogenicity of the marine biotoxin azaspiracid-2 in rats.

Authors:  Sara F Ferreiro; Natalia Vilariño; Cristina Carrera; M Carmen Louzao; Germán Santamarina; Antonio G Cantalapiedra; Laura P Rodríguez; J Manuel Cifuentes; Andrés C Vieira; K C Nicolaou; Michael O Frederick; Luis M Botana
Journal:  Arch Toxicol       Date:  2013-08-11       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.